Literature DB >> 26381681

Treatment of bacterial skin infections in ED observation units: factors influencing prescribing practice.

John P Haran1, Gregory Wu2, Vanni Bucci3, Andrew Fischer2, Edward W Boyer2, Patricia L Hibberd4.   

Abstract

OBJECTIVE: The Infectious Disease Society of America (IDSA) publishes evidence-based guidelines for the treatment of skin and soft tissue infections. How closely physicians follow these guidelines is unknown, particularly in the emergency department observation unit (EDOU) where increasing numbers of patients are treatment for these infections. Our objectives were to describe (1) the antibiotic treatment patterns EDOU patients, (2) physicians' adherence to the IDSA guidelines, and (3) factors that influence physician's prescribing practices.
METHODS: This prospective cohort enrolled adult patients discharged from an EDOU at an academic medical center after treatment for a skin or soft tissue infection. Information was collected from chart review and patient interview pertaining to the patient's sociodemographic characteristics, presenting illness, and antibiotic treatment regimens. Treatment regimens were compared with national guidelines.
RESULTS: The study included 193 patients of which only 43% were treated according to IDSA guidelines, 42% were overtreated, and 15% were undertreated. Women were more likely to be undertreated (relative risk, 1.58; 95% confidence interval, 1.21-2.06), whereas patients 50 years and older were at risk for overtreatment (relative risk, 1.44; 95% confidence interval, 1.03-2.02). Women also received shorter courses of antibiotic therapy with an average of 9.6 days of treatment compared with 10.6 days for men.
CONCLUSIONS: Physician antibiotic prescribing practices demonstrated poor adherence to IDSA guidelines and were influenced by the patient's age and sex. Standardized antibiotic protocols for treatment of skin and soft tissue infections to IDSA guidelines in the EDOU would minimize physician bias.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26381681      PMCID: PMC4679601          DOI: 10.1016/j.ajem.2015.08.035

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  27 in total

1.  The use and effectiveness of an emergency department observation unit for elderly patients.

Authors:  Michael A Ross; Scott Compton; Daniel Richardson; Ryan Jones; Tara Nittis; Andrew Wilson
Journal:  Ann Emerg Med       Date:  2003-05       Impact factor: 5.721

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 3.  Clostridium difficile infection in the elderly.

Authors:  Jonathan M Keller; Christina M Surawicz
Journal:  Clin Geriatr Med       Date:  2014-02       Impact factor: 3.076

4.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

Authors:  Hude Quan; Bing Li; Chantal M Couris; Kiyohide Fushimi; Patrick Graham; Phil Hider; Jean-Marie Januel; Vijaya Sundararajan
Journal:  Am J Epidemiol       Date:  2011-02-17       Impact factor: 4.897

5.  Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.

Authors:  J Wiström; S R Norrby; E B Myhre; S Eriksson; G Granström; L Lagergren; G Englund; C E Nord; B Svenungsson
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

6.  Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics.

Authors:  John Patrick Haran; Gregory Hayward; Stephen Skinner; Chris Merritt; David C Hoaglin; Patricia L Hibberd; Shan Lu; Edward W Boyer
Journal:  Am J Emerg Med       Date:  2014-07-30       Impact factor: 2.469

7.  Physicians' perceptions of patients' social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease.

Authors:  Michelle van Ryn; Diana Burgess; Jennifer Malat; Joan Griffin
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

8.  Integrative "omic" analysis of experimental bacteremia identifies a metabolic signature that distinguishes human sepsis from systemic inflammatory response syndromes.

Authors:  Raymond J Langley; Jennifer L Tipper; Shannon Bruse; Rebecca M Baron; Ephraim L Tsalik; James Huntley; Angela J Rogers; Richard J Jaramillo; Denise O'Donnell; William M Mega; Mignon Keaton; Elizabeth Kensicki; Lee Gazourian; Laura E Fredenburgh; Anthony F Massaro; Ronny M Otero; Vance G Fowler; Emanuel P Rivers; Chris W Woods; Stephen F Kingsmore; Mohan L Sopori; Mark A Perrella; Augustine M K Choi; Kevin S Harrod
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Predicting observation unit treatment failures in patients with skin and soft tissue infections.

Authors:  Jon W Schrock; Sara Laskey; Rita K Cydulka
Journal:  Int J Emerg Med       Date:  2008-06-17
View more
  2 in total

1.  Deviating from IDSA treatment guidelines for non-purulent skin infections increases the risk of treatment failure in emergency department patients.

Authors:  J P Haran; E Wilsterman; T Zeoli; M Goulding; E McLendon; M A Clark
Journal:  Epidemiol Infect       Date:  2018-12-05       Impact factor: 2.451

Review 2.  Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline.

Authors:  Monique R Bidell; Thomas P Lodise
Journal:  Pharmacotherapy       Date:  2021-10-05       Impact factor: 6.251

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.